Editas Medicine (NASDAQ:EDIT) Trading Up 10.5% – What’s Next?

Posted by Geri Gentry on Aug 25th, 2026

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) shares shot up 10.5% on Tuesday . The stock traded as high as $3.27 and last traded at $3.3160. 1,261,704 shares traded hands during trading, a decline of 39% from the average session volume of 2,077,548 shares. The stock had previously closed at $3.00.

Analyst Ratings Changes

A number of research analysts have recently issued reports on EDIT shares. Chardan Capital lifted their price objective on shares of Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings upgraded shares of Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. TD Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a research report on Wednesday, May 27th. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, LADENBURG THALM/SH SH initiated coverage on Editas Medicine in a report on Tuesday, August 18th. They set a “buy” rating and a $6.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Check Out Our Latest Analysis on Editas Medicine

Editas Medicine Stock Performance

The firm has a market capitalization of $490.69 million, a P/E ratio of -4.26 and a beta of 2.14. The firm has a 50 day simple moving average of $2.95 and a two-hundred day simple moving average of $2.71.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.12. The firm had revenue of $11.89 million during the quarter, compared to analyst estimates of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. Sell-side analysts anticipate that Editas Medicine, Inc. will post -0.85 earnings per share for the current year.

Insider Transactions at Editas Medicine

In other Editas Medicine news, CEO Gilmore Neil O’neill sold 15,380 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the completion of the sale, the chief executive officer directly owned 248,313 shares of the company’s stock, valued at approximately $670,445.10. This represents a 5.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 21,503 shares of company stock valued at $57,910. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Editas Medicine

A number of hedge funds and other institutional investors have recently modified their holdings of EDIT. GSA Capital Partners LLP bought a new position in shares of Editas Medicine in the second quarter worth $1,190,000. Renaissance Technologies LLC raised its stake in Editas Medicine by 30.7% in the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock valued at $9,811,000 after purchasing an additional 932,382 shares in the last quarter. Eversept Partners LP purchased a new stake in Editas Medicine in the fourth quarter valued at approximately $596,000. Walleye Capital LLC bought a new stake in Editas Medicine during the second quarter valued at approximately $596,000. Finally, SCS Capital Management LLC purchased a new position in Editas Medicine in the 2nd quarter worth approximately $113,000. Hedge funds and other institutional investors own 71.90% of the company’s stock.

About Editas Medicine

(Get Free Report)

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.